Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) Other Operating Expenses (2016 - 2023)

Celldex Therapeutics has reported Other Operating Expenses over the past 14 years, most recently at $12.5 million for Q4 2023.

  • Quarterly results put Other Operating Expenses at $12.5 million for Q4 2023, up 157.08% from a year ago — trailing twelve months through Sep 2024 was $12.5 million (up 157.08% YoY), and the annual figure for FY2023 was -$12.5 million, up 16.67%.
  • Other Operating Expenses for Q4 2023 was $12.5 million at Celldex Therapeutics, up from -$21.9 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for CLDX hit a ceiling of $12.5 million in Q4 2023 and a floor of -$21.9 million in Q4 2022.
  • Median Other Operating Expenses over the past 5 years was -$108000.0 (2020), compared with a mean of -$1.1 million.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 1261.11% in 2021 and later plummeted 9038.78% in 2022.
  • Celldex Therapeutics' Other Operating Expenses stood at -$318000.0 in 2019, then soared by 105.66% to $18000.0 in 2020, then skyrocketed by 1261.11% to $245000.0 in 2021, then plummeted by 9038.78% to -$21.9 million in 2022, then surged by 157.08% to $12.5 million in 2023.
  • The last three reported values for Other Operating Expenses were $12.5 million (Q4 2023), -$21.9 million (Q4 2022), and -$15.0 million (Q2 2022) per Business Quant data.